Home › NCT07382349

A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease

Randomized Controlled Trial of Electronic Clinical Decision Support Systems for Improving Care Management and Clinical Outcomes for Adults With Steatotic Liver Disease

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients (age ≥ 18 years)
* Outpatient clinic visit (in-person or telemedicine) at a participating clinic site
* Demonstrated Screening Need due to High Risk Profile, which includes the following: Diagnostic Codes for MASLD or Hepatic Steatosis on Imaging PLUS at least one cardiometabolic risk factors; OR Chronically Elevated Liver Enzymes (\> 6 months); OR patient with impaired glycemic control (prediabetes/diabetes); OR 2 or more cardiometabolic risk factors present

Exclusion Criteria:

* Solid Organ Transplant Recipient
* Existing Hepatology Relationship Evidenced by Prior Hepatology Visit Within 3 Years
* Active Cancer Diagnoses
* Diagnoses for Alcohol-Related Conditions
* Pregnant Individuals
* Receiving Palliative Care Services

About the study

The overall objectives of this study are to determine the effectiveness of a participant-specific guided electronic decision support system on provider decision making for participants with metabolic-dysfunction associated steatotic liver disease (MASLD), and to determine the acceptance and barriers for use of an electronic health record embedded algorithm for MASLD care management within ambulatory primary care, endocrinology, and general gastroenterology settings.

What is being tested

• eMPOWER Decision Aid (other)

Sponsor: Vanderbilt University Medical Center · Participants: 7,200 · Started: Jul 20, 2026

Contact the study team

• Michael McGill · Phone: 6153224643

Official record on ClinicalTrials.gov — NCT07382349

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.